| 1 | Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8 |
| 2 | Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396 |
| 3 | Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2019; doi: 10.1007/s10334-019-00817-4 |
| 4 | Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459 |
| 5 | Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2019; doi: 10.1007/s40883-019-00113-6 |
| 6 | Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002 |
| 7 | Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7 |
| 8 | Novel therapeutic strategies for spinal osteosarcomas. 2019; doi: 10.1016/j.semcancer.2019.05.018 |
| 9 | The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646 |
| 10 | Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6 |
| 11 | Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0 |
| 12 | Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4 |
| 13 | Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139 |
| 14 | Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3 |
| 15 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105 |
| 16 | Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877 |
| 17 | MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019 |
| 18 | Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D |
| 19 | Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433 |
| 20 | Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006 |
| 21 | Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7 |
| 22 | CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2019; doi: 10.1093/bfgp/elz039 |
| 23 | Editorial. 2019;12:3 doi: 10.1111/ors.12402 |
| 24 | Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524 |
| 25 | Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3 |
| 26 | Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240 |
| 27 | The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965 |
| 28 | Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4 |